Author/Creator: Taylor, Peter C - British Library Electronic Legal Deposit Catalogue-Journal Issues and Articles Search Results

Author/Creator Taylor, Peter C

11. Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis. (26th February 2019)

Authors:: Taylor, Peter C
Journal:: Rheumatology
Issue:: Volume 58(2019)Supplement 1
Page Start:: i17
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

12. Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis. Issue 7 (30th April 2019)

Authors:: Tanaka, Yoshiya; Fautrel, Bruno; Keystone, Edward C; Ortmann, Robert A; Xie, Li; Zhu, Baojin; Issa, Maher; Patel, Himanshu; Gaich, Carol L; de Bono, Stephanie; Rooney, Terence P; Taylor, Peter C
Journal:: Annals of the rheumatic diseases
Issue:: Volume 78:Issue 7(2019)
Page Start:: 890
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

13. Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis. Issue 7 (30th July 2019)

Authors:: Tanaka, Yoshiya; Fautrel, Bruno; Keystone, Edward C; Ortmann, Robert A; Xie, Li; Zhu, Baojin; Issa, Maher; Patel, Himanshu; Gaich, Carol L; de Bono, Stephanie; Rooney, Terence P; Taylor, Peter C
Journal:: Annals of the rheumatic diseases
Issue:: Volume 78:Issue 7(2019)
Page Start:: 890
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

14. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis. Issue 9 (14th September 2012)

Authors:: Pathan, Ejaz; Abraham, Sonya; Van Rossen, Elizabeth; Withrington, Robin; Keat, Andrew; Charles, Peter J; Paterson, Erin; Chowdhury, Muslima; McClinton, Catherine; Taylor, Peter C
Journal:: Annals of the rheumatic diseases
Issue:: Volume 72:Issue 9(2013)
Page Start:: 1475
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

15. Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study. Issue 8 (8th August 2019)

Authors:: Glatt, Sophie; Taylor, Peter C; McInnes, Iain B; Schett, Georg; Landewé, Robert; Baeten, Dominique; Ionescu, Lucian; Strimenopoulou, Foteini; Watling, Mark I L; Shaw, Stevan
Journal:: Annals of the rheumatic diseases
Issue:: Volume 78:Issue 8(2019)
Page Start:: 1033
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

16. Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study. Issue 8 (8th June 2019)

Authors:: Glatt, Sophie; Taylor, Peter C; McInnes, Iain B; Schett, Georg; Landewé, Robert; Baeten, Dominique; Ionescu, Lucian; Strimenopoulou, Foteini; Watling, Mark I L; Shaw, Stevan
Journal:: Annals of the rheumatic diseases
Issue:: Volume 78:Issue 8(2019)
Page Start:: 1033
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

17. Efficacy and safety of monotherapy with sirukumab compared with adalimumab monotherapy in biologic-naïve patients with active rheumatoid arthritis (SIRROUND-H): a randomised, double-blind, parallel-group, multinational, 52-week, phase 3 study. Issue 5 (26th February 2018)

Authors:: Taylor, Peter C; Schiff, Michael H; Wang, Qingmin; Jiang, Yusang; Zhuang, Yanli; Kurrasch, Regina; Daga, Shruti; Rao, Ravi; Tak, Paul P; Hsu, Benjamin
Journal:: Annals of the rheumatic diseases
Issue:: Volume 77:Issue 5(2018)
Page Start:: 658
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

18. Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: results from a long-term study . (17th November 2020)

Authors:: Smolen, Josef S; Xie, Li; Jia, Bochao; Taylor, Peter C; Burmester, Gerd; Tanaka, Yoshiya; Elias, Ayesha; Cardoso, Anabela; Ortmann, Rob; Walls, Chad; Dougados, Maxime
Journal:: Rheumatology
Issue:: Volume 60:Number 5(2021)
Page Start:: 2256
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

19. Et tu, Brutinib? Demise of a kinase target in rheumatoid arthritis?. (May 2023)

Authors:: Taylor, Peter C
Journal:: Lancet
Issue:: Volume 5:Number 5(2023)
Page Start:: e241
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

20. Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPARE. (26th August 2022)

Authors:: Mysler, Eduardo; Tanaka, Yoshiya; Kavanaugh, Arthur; Aletaha, Daniel; Taylor, Peter C; Song, In-Ho; Shaw, Tim; Song, Yanna; DeMasi, Ryan; Ali, Mira; Fleischmann, Roy
Journal:: Rheumatology
Issue:: Volume 62:Number 5(2023)
Page Start:: 1804
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗